Application of cajanonic acid B in preparation of medicine for treating non-alcoholic fatty liver disease

By using Shudouke acid B to intervene in the non-alcoholic fatty liver disease model, the levels of fat deposition, inflammation and oxidative stress were reduced, and the problem of insufficient effect of existing drugs on non-alcoholic fatty liver disease was solved, and the effectiveness of this disease was achieved Prevention and treatment.

CN118948820AInactive Publication Date: 2024-11-15GUIZHOU MEDICAL UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411041235.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing non-alcoholic fatty liver disease drugs have no obvious effect on this disease, especially the aromatic ring-substituted ketoacid A derivative is mainly targeted at type 2 diabetes and its complications, and has not effectively prevented or treated non-alcoholic fats. Liver disease.

Method used

Using ketoketolic acid B, by intervening in vivo and in vivo models, reduce fat deposition, inflammation, oxidative stress and fibrosis levels, and improve liver pathological status, as a new purpose in preventing or treating non-alcoholic fatty liver disease.

Benefits of technology

Shrukalic acid B significantly reduces the levels of liver steatosis, inflammation and oxidative stress, and prevents or treats non-alcoholic fatty liver disease through multiple effects, and has the potential to develop new anti-NAFLD products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948820A_ABST
    Figure CN118948820A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of cajanonic acid B in preparation of a medicine for treating a non-alcoholic fatty liver disease. The invention provides a new application of cajanonic acid B; cell and animal experiments prove that the cajanonic acid B can reduce liver fatty degeneration, improve liver inflammation, oxidative stress and fibrosis levels for the first time, prevents or treats NAFLD through multiple effects, has great potential of being developed into a novel anti-NAFLD product, and can obtain good economic and social benefits.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and particularly relates to the application of scutellaria baicalenic acid B in preparing a drug for preventing or treating non-alcoholic fatty liver disease. Background Art

[0002] Non-alcoholic fatty liver disease (NAFLD) is a progressive metabolic disease characterized by fatty degeneration of hepatocytes. Its prevalence and incidence have continued to rise in recent years, making it the most common chronic liver disease in the world.

[0003] NAFLD has a wide spectrum of clinical manifestations, ranging from early non-alcoholic fatty liver or simple steatosis to the second stage of non-alcoholic fatty liver hepatitis, and then to liver fibrosis and cirrhosis. This process may lead to end-stage liver disease or develop into hepatocellular carcinoma. Factors that lead to the occurrence and development of NAFLD include genetics, unhealthy diet and lifestyle, endocrine and hormonal disorders caused by emotions and mental stress, etc., involving the joint action of multiple organs such as liver, intestines, adipose tissue and multiple types of cells in the body. The exact pathogenesis of NAFLD is still unclear. Tilg et al. proposed the "multiple parallel strikes" theory in 2010. The theory believes that NAFLD is caused by a series of parallel factors, including lipid metabolism disorders, lipotoxicity, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, intestinal endogenous endotoxins, abnormal secretion of cytokines and adipokines, genetic susceptibility and other factors, which are all considered to play a key role in the occurrence and development of NAFLD.

[0004] Nowadays, there are also some studies on non-alcoholic fatty liver drugs, such as the patent document with publication number CN117682950A, which discloses aromatic (hetero) ring-substituted scutellaria ketoacid A derivatives, pharmaceutical compositions, preparation methods and applications thereof, which can be used as PPARγ antagonists, can improve the PPARγ antagonistic activity and insulin sensitizing activity of the compounds, and also have good drug properties, providing better options for the treatment of metabolic syndrome, type 2 diabetes and its complications, non-alcoholic fatty liver disease, obesity and other diseases. However, this type of compound is mainly studied for type 2 diabetes and its complications, and the effect on non-alcoholic fatty liver disease is not very obvious.

[0005] In view of this, the present invention provides a product with multiple effects for preventing or treating NAFLD. Summary of the invention

[0006] To solve the above problems, the present invention proposes the use of oxadiazine B in the preparation of products for treating non-alcoholic steatohepatitis, that is, oxadiazine B can reduce liver fatty degeneration, improve liver inflammation, oxidative stress and fibrosis levels, and confirms that oxadiazine B prevents or treats NAFLD through multiple effects.

[0007] The chemical structure of the ketoconic acid B is:

[0008]

[0009] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0010] According to the pathogenesis and clinical symptoms of NAFLD, relevant in vivo and in vitro models were constructed, and arbutin B was used for intervention, and its improvement effect was evaluated.

[0011] As a preferred technical solution, the arbutin B can effectively reduce fat deposition and the levels of total cholesterol (TC) and triglycerides (TG) in the NAFLD cell model.

[0012] As a preferred technical solution, the scutellaria baicalenic acid B can effectively reduce the levels of NO and IL-6 in the inflammatory cell model.

[0013] As a preferred technical solution, the scutellaria baicalenic acid B can effectively reduce the MDA and SOD levels of the oxidative stress model.

[0014] As a preferred technical solution, the scutellaria baicalenic acid B can effectively reduce the expression level of the fibrotic marker FN protein in the fibrosis cell model.

[0015] As a preferred technical solution, the arbutin B can effectively reduce liver function biochemical indicators such as TC, TG, LDL-C, HDL-C, AST, ALT, IL-1β, TNF-α and IL-6 in a NAFLD mouse model induced by high-fat feeding (HF60), and improve liver pathological conditions.

[0016] The scutellaria ketoacid B of the present invention includes but is not limited to the compound shown in the above chemical structure, or its geometric isomers, tautomers, isotope-labeled substances, hydrates, solvates, polymorphs, metabolites, prodrugs, pharmaceutically acceptable salts or esters.

[0017] The use of scutellaria baicalenic acid B in the preparation of a product for preventing or treating non-alcoholic fatty liver disease comprises scutellaria baicalenic acid B and pharmaceutically acceptable excipients.

[0018] Furthermore, the pharmaceutically acceptable excipients include but are not limited to conventional pharmaceutical fillers, diluents,

[0019] Release agents, binders, excipients, penetration enhancers, absorption enhancers, surfactants, pH adjusters, antioxidants, stabilizers, chelating agents, propellants, pore-forming agents, film-forming agents, solvents, co-solvents, flavoring agents, sweeteners, pigments, etc.

[0020] The present invention also provides the above-mentioned scutellaria ketoacid B as a preparation of medicine and as a food. The preparation of medicine can be prepared by conventional preparation methods in the art in the form of compound decoction for oral administration, granules, tablets, granules, powders, capsules, oral liquids, pills, nasogastric feeding, anal suppositories, rectal irrigation, local external administration, navel sticking, Chinese medicine fumigation, external foot bath and other common drug dosage forms; as a food form, it can be prepared by conventional preparation methods in the art in the form of conventional food forms such as tea bags, liquid or solid beverages, special nutritional foods and the like.

[0021] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0022] The present invention provides a new use of scutellaria quinoline B; scutellaria quinoline B has the effect of antagonizing the binding of rosiglitazone to PPARγ, but its preventive and therapeutic effects on NAFLD have not been reported in the literature. The present invention first confirms through cell and animal experiments that scutellaria quinoline B can reduce liver fatty degeneration, improve liver inflammation, oxidative stress and fibrosis levels, prevent or treat NAFLD through multiple effects, and has great potential for development into a new anti-NAFLD product, which can achieve good economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The effect of oxadiazine B on fat deposition in NAFLD cell model.

[0024] Figure 2 This is the effect of oxadiazine B on TC and TG levels in NAFLD cell model.

[0025] Figure 3 The effect of oxadiazine B on cellular oxidative stress.

[0026] Figure 4 The effect of oxadiazine B on inflammatory cell model.

[0027] Figure 5 The effect of oxadiazine B on fibrotic cell model.

[0028] Figure 6 To investigate the effect of oxadiazine B on body weight in NAFLD animal model.

[0029] Figure 7 To investigate the effects of oxadiazine B on liver imaging in an animal model of fibrotic NAFLD.

[0030] Figure 8This is the effect of oxadiazine B on biochemical levels in NAFLD model mice.

[0031] Fig. 9 Effects of oxadiazine B on fatty degeneration and morphology of liver tissue in NAFLD model mice DETAILED DESCRIPTION

[0032] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. It should be understood by those skilled in the art that the following specific description is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0033] Example 1 Effect of oxadiazine B on fat deposition in NAFLD cell model

[0034] HepG2 cells in the logarithmic growth phase were seeded in a 96-well plate, with approximately 3 × 10 4 10% FBS high-glucose medium was used to culture the cells to adhere to the wall and fuse, and the serum-free medium was replaced for assimilation for 12 hours. 1mM FFAs medium (OA:PA=2:1) ​​was replaced, and the cells were divided into solvent group (Control), model group (Model), rosiglitazone group (Rosi 10μM), different concentrations of fenofibrate groups (FNB 0.1μM, 1μM, 10μM) and different concentrations of cabonucleic acid B groups (CAB 0.1μM, 1μM, 10μM). The cells in each treatment group were cultured in an incubator for 24 hours, washed twice with PBS buffered saline, fixed with 4% paraformaldehyde for 30 minutes, washed with 60% isopropanol, dried, and stained with 0.2% Oil Red O reagent at 24℃ for 10 minutes, and washed with water 4 times. Photographed under a microscope, and the relative area of ​​lipid droplets was analyzed using Image software.

[0035] The results are as follows Figure 1 As shown in the figure, compared with the solvent group, the lipid content in the model group cells increased significantly, and rosiglitazone treatment further increased cellular lipid formation. After treatment with fenofibrate and cypermethrin B, the intracellular lipid level of the group decreased in a dose-dependent manner, indicating that cypermethrin B can effectively reduce the deposition of lipids in hepatocytes and significantly improve hepatocyte fatty degeneration.

[0036] Example 2 Effect of oxadiazine B on TC and TG levels in NAFLD cell models

[0037] When the density of HepG2 cells in the culture flask reached 80%, the cells were digested and subcultured. 5Cells were inoculated in a 6-well plate at a density of 100 cells / well, and 2 mL of complete medium was added to each well. The cells were cultured in a cell culture incubator for 12 h, and 1 mM FFAs medium (OA:PA=2:1) ​​was replaced. The cells were divided into a solvent group (Control), a model group (Model), a fenofibrate group (FNB 10 μM) and a caespitone acid B group (CAB 10 μM). The cells in each treatment group were cultured in an incubator for 24 h. The culture medium was discarded and washed three times with PBS. 300 μL of RIPA lysis buffer was added to each well. All cells and lysis buffer in the well plate were scraped off with a cell scraper and transferred to a 2 mL EP tube. The cells were further broken by ultrasonic cell disruptor with a power of 40-50 Hz on ice for 1 min. After the cells were completely broken, they were directly measured according to the instructions of the TC and TG kits. The remaining lysate was centrifuged at 12000 g / min at 4 ° C for 10 min, and the supernatant was collected. The total amount of sample protein was detected according to the instructions of the BCA kit for data correction.

[0038] The results are as follows Figure 2 As shown in the figure, it can be seen that when the cells were induced by medium containing FFAs, the TC and TG contents increased significantly. When the cells were treated with 10 μM concentration of fenofibrate or cynarin B, the TC and TG contents decreased significantly, and the change of cynarin B on TG was more obvious.

[0039] Example 3 Effect of scutellaria baicalenic acid B on oxidative stress cell model

[0040] When the density of HepG2 cells in the culture flask reached 80%, the cells were digested and subcultured. 5 The cells were inoculated at a density of 100 cells / well in a 6-well plate, 2 mL of complete medium was added to each well, and the cells were cultured in a cell culture incubator for 18 h. The serum-free medium was replaced for assimilation treatment for 12 h, and 1 mM FFAs medium (OA:PA=2:1) ​​was replaced. The cells were divided into a solvent group (Control), a model group (Model), a fenofibrate group (FNB 10 μM) and a caesalpinia acid B group (CAB 10 μM). The cells in each treatment group were cultured in an incubator for 48 h, and the supernatant of the cells in each group was collected and detected according to the steps in the instructions of the SOD and MDA detection kits.

[0041] The results are as follows Figure 3 As shown in the results, FFAs induced cellular oxidative stress during lipogenesis, with a decrease in SOD levels and an increase in MDA levels. After treatment with scutellaria baicalensis B, the levels of SOD and MDA in cells were restored, but fenofibrate did not significantly change them, indicating that scutellaria baicalensis B has a significant antioxidant effect.

[0042] Example 4 Effect of oxadiazine B on Inflammatory Cell Model

[0043] 4×10 mouse RAW264.7 cells per well 4 The cells were inoculated in 96-well plates and cultured for 12 hours to adhere to the wall. The original culture medium was aspirated, gently rinsed with 100 μL PBS, and replaced with 100 μL serum-free culture medium to treat the cells for 12 hours. The cells were divided into solvent group (Control), model group (Model), dexamethasone (DEX 10 μM) and cabonucleic acid B group (CAB 10 μM), with 4 replicates in each group. After culturing in the incubator for 2 hours, LPS with a final concentration of 1 μg / ml was added. The normal group was added with an equal volume of DMEM culture medium. After continuing to culture the cells for 24 hours, the NO release in the supernatant was detected using a NO kit, and the IL6 secretion in the supernatant was detected using an ELISA kit.

[0044] The results are as follows Figure 4 As shown in the figure, it can be seen that when the cells were stimulated with LPS, the NO release and IL-6 levels increased significantly. When the cells were treated with 10μM concentration of dexamethasone or cypermethrin B, the NO and IL-6 levels decreased significantly, indicating that cypermethrin B has obvious anti-inflammatory activity.

[0045] Example 5 Effect of scutellariae acid B on fibrosis cell model

[0046] LX-2 cells were cultured to a density of about 90% using 10% FBS high-glucose medium, and 10ng / ml TGF-β was added to induce LX-2 cell activation to establish a liver fibrosis model. The cells were divided into a solvent group (Control), a model group (Model), a pirfenidone (DEX 100μM) and a caesalpinoic acid B group (CAB 10μM), and treated with drugs or blank solvent for 24h. The culture medium was discarded, 80ul RIPA lysis buffer and PMSF were added to extract protein, and the cells were shaken and lysed on ice for 30min, centrifuged at 10000rpm for 10min at 4℃, and the supernatant was quantified using the BCA method. After the protein was denatured by boiling at 100°C, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and membrane transfer were performed; the membrane was blocked with rapid blocking solution at room temperature for 1 hour, and mixed primary antibodies of FN and β-actin (dilution of 1:1000) were added, and incubated at 4°C overnight; the membrane was washed 3 times with TBST, each time for 5 minutes, and secondary antibodies (dilution of 1:10000) were added, and incubated at room temperature for 1 hour; the membrane was washed 3 times with TBST, each time for 5 minutes, and the image was taken using Image Studio Ver 5.2 imaging analyzer and analyzed with ImageJ 6.0 software. The expression level of FN protein was represented by the grayscale ratio of FN protein to the internal reference β-actin.

[0047] The results are as follows Figure 5As shown, TGF-β induced LX-2 cell activation and significantly increased the expression level of the fibrosis marker single-band FN. The scutellaria baicalensis acid B was able to reduce the expression of cellular FN protein, and its activity was better than that of the anti-fibrotic drug pirfenidone, indicating that the scutellaria baicalensis acid B has an anti-liver fibrosis effect.

[0048] Example 6 Effect of oxadiazine B on NAFLD animal model

[0049] Animal treatment of male C57BL / 6J mice: 40 6-week-old C57BL / 6J male mice (20±2 g) were purchased from the Experimental Animal Center of Guizhou Medical University (Ethics Review Approval No.: NO 2400070). Adaptive feeding was performed for 1 week. The mice were kept in an SPF animal room with a relative humidity of 30-70% and a temperature of 25 degrees Celsius. The room was light and dark for 12 hours, and they were free to eat and drink. Eight mice were used as normal controls and fed with regular feed. The other 32 mice were given a HFD60 diet to induce NAFLD models for 12 weeks. The animals were divided into 4 groups according to their weight levels (model group, obeticholic acid group, fenofibrate group, and cypermethrin B group). The control group and the model group were gavaged with blank solvent; the drug-treated group was given 30 mg / kg of the corresponding drug for 16 weeks. The weight of the mice was recorded during the period. At the end of the drug administration, imaging blood, biochemical and pathological examinations were used to evaluate the drug activity.

[0050] Body weight: The body weight of the NAFLD animal model induced by a high-fat diet for 12 weeks was significantly higher than that of the normal diet. After 16 weeks of drug administration, the body weight of the model group increased further. The obeticholic acid group, fenofibrate group, and arbutin B group were able to reduce the body weight of the animals. The results are as follows: Figure 6 shown.

[0051] Imaging examination: After fasting for 2 hours, the animals were anesthetized by inhalation of isoflurane. The hair from the xiphoid process to the upper part of the right hind leg of the mouse was removed to fully expose the abdomen. The mouse was fixed in the left lateral position. The center of the LM24-6WU probe of the Mindray ultrasound imaging system was placed 1 cm to the left of the right axilla of the mouse. The probe frequency was 23MHz. Under the conditions of a depth of 2.5cm, a frame rate of 49, a dynamic range of 125, and a gain of 58dB, the probe was moved to detect the right lobe of the liver, and a cross-sectional image was taken to observe the two-dimensional grayscale image of the liver.

[0052] The results are shown in Figure 7. Through two-dimensional liver-kidney section observation, the liver echo of mice on a normal diet was lower than the renal cortex echo, and the liver echo of mice in the model group was stronger than the renal cortex echo. After giving fenofibrate and scutellariae B, the echo of the animal liver decreased, indicating that liver fatty degeneration improved.

[0053] Biochemical examination: The mice were fasted for 12 hours. Two hours after administration, the whiskers of the mice were cut with ophthalmic scissors to prevent hemolysis. The eyeballs of the mice were removed and blood was collected into 1.5 mL of EP (on ice) containing anticoagulant (sodium citrate configuration: weigh 380 mg and dissolve in 10 mL of normal saline. Anticoagulant volume: blood volume = 1:9), centrifuged at 4°C and 4000 rpm for 15 minutes, and the upper serum was taken. TC, TG, LDL-C, HDL-C, AST, and ALT were detected according to the instructions of the kit. The abdominal cavity of the mouse was opened, and the liver tissue (20 mg) was taken. 200 μL of normal saline (9 times the volume) was added, and it was ground into a homogenate at low temperature. The levels of IL-1β, TNF-α, and IL-6 inflammatory factors were detected using an ELISA kit.

[0054] The results are as follows Figure 8 As shown, scutellaria ketoacid B can reduce the levels of TC, TG, LDL-C, AST, and ALT in the serum of NAFLD mice, and increase the level of HDL-C, indicating that scutellaria ketoacid B has lipid-lowering and liver-protective effects, and its activity is better than that of positive drugs fenofibrate and obeticholic acid. Scutellaria ketoacid B can reduce the levels of IL-1β, TNF-α, and IL-6 in the liver of NAFLD mice, and its activity is better than that of positive drugs fenofibrate and obeticholic acid, indicating that scutellaria ketoacid B has the effect of improving liver inflammation in NAFLD mice.

[0055] Animal pathological examination: The right lobe of the liver was taken, embedded, sectioned, and then stained with Oil Red O and HE for pathological examination.

[0056] The results are as follows Fig. 9 As shown in the results, high-fat diet led to a significant increase in fat deposition in animal liver tissues, and fat droplets were significantly reduced after administration. Among them, the activity of fenofibrate and arbutin B was the most obvious, indicating that fenofibrate and arbutin B had the effect of improving liver fatty degeneration in NAFLD mice induced by high-fat diet. HE staining showed that the liver cells of mice in the normal group had normal morphology, large, round, centered nuclei, and uniform quality. The liver cords of mice in the model group were disordered, the volume of liver cells increased, and a large number of cells showed typical vacuolar degeneration; compared with the model group, the liver cell structure of mice in the drug administration group was relatively complete, the cell volume decreased, and the vacuolar degeneration was significantly improved, indicating that arbutin B, fenofibrate, and obeticholic acid had a certain protective effect on the liver cells of mice fed a high-fat diet.

Claims

1. Use of ketoconazole B in the preparation of a drug for preventing or treating non-alcoholic fatty liver disease, characterized in that: The chemical structure of the ketoconic acid B is:

2. The use of scutellaria baicalenic acid B according to claim 1 in the preparation of a drug for preventing or treating non-alcoholic fatty liver disease, characterized in that: The scutellaria ketoacid B includes but is not limited to the compound according to claim 1, or its geometric isomers, tautomers, isotope labels, hydrates, solvates, polymorphs, metabolites, prodrugs, pharmaceutically acceptable salts or esters.

3. The use of scutellaria baicalenic acid B according to claim 1 in the preparation of a drug for preventing or treating non-alcoholic fatty liver disease, characterized in that: The medicine is prepared by combining scutellaria ketoacid B with pharmaceutically acceptable auxiliary materials to prepare the required preparation.

4. Use of the ketoconazole acid B as claimed in claim 1 in preparing a food for assisting in improving non-alcoholic fatty liver disease.

Citation Information

Patent Citations

  • Application of pigeon pea ketonic acid A in terms of preparation of medicines for accompanied diseases of diabetes mellitus and hyperlipidaemia

    CN102670576A

  • Cajanonic acid A analog, composition thereof and application thereof in drugs

    CN106397207A

  • Aromatic (hetero) ring substituted cajanus ketonic acid A derivative, pharmaceutical composition, and preparation method and application of cajanus ketonic acid A derivative

    CN117682950A